Choosing the Right Travel & Expense Partner for Clinical Trials

For sponsors, clinical trial success is often evaluated through a familiar lens: enrollment timelines, retention rates, protocol adherence, and data quality. But behind each of these metrics is an operational layer that is frequently underestimated, how patients physically and financially get to and from the trial.

Travel and expense (T&E) management is no longer a back-office function. In complex, global, and oncology studies, it has become a critical component of trial execution strategy.

Choosing the right T&E partner can directly influence study performance.

Why Travel & Expense Execution Matters to Sponsors

Even the most well-designed protocol depends on consistent participant attendance and engagement. When travel logistics or reimbursement processes break down, the impact is immediate and measurable:

• Missed or delayed visits
• Increased site workload
• Higher dropout risk
• Slower enrollment in competitive indications
• Reduced data completeness

From a sponsor perspective, these are not isolated operational issues, they are drivers of cost and timeline variability.

What Typically Differentiates T&E Partners in Clinical Trials

1. Ability to Operate Within Protocol Complexity

Not all trials are equally travel-intensive. Sponsors should assess whether a provider can adapt to:

• High-frequency visit schedules
• Multi-site or cross-border participation
• Specialized site networks (e.g., oncology, rare disease)
• Last-minute protocol changes or unscheduled visits

A strong partner understands that travel support must mirror protocol demands, not the other way around.

2. Global Scalability with Local Precision

As trials expand geographically, consistency becomes critical. Sponsors should look for providers that can:

• Coordinate travel across multiple regions and regulatory environments
• Maintain standardized processes while adapting to local requirements
• Ensure consistent patient experience regardless of geography

Inconsistent execution across regions often translates into inconsistent data.

3. Financial Flow That Reduces Participant Friction

One of the most common sources of participant dropout is financial burden. Sponsors should evaluate how a provider manages:

• Upfront payment of travel and lodging where appropriate
• Reimbursement timelines and transparency
• Reduction of out-of-pocket expenses for participants

Delays or complexity in reimbursement are not administrative issues, they are retention risks.

4. Operational Integration with Sites and Study Teams

A T&E partner should not operate in isolation. Sponsors should prioritize vendors that integrate smoothly with:

• Site coordinators and clinical staff
• Clinical operations teams

Poor integration often results in duplicated work, communication gaps, and inconsistent participant support.
How the Right Partner Impacts Trial Outcomes

When travel and expense operations are well executed, the effects extend beyond logistics:

• Improved enrollment feasibility in geographically diverse populations
• Higher retention and fewer avoidable dropouts
• Reduced site burden and improved operational focus
• Greater consistency in visit adherence and protocol execution
• More stable and predictable trial timelines

In many studies, T&E execution becomes a differentiator between trials that struggle with attrition and those that maintain stable participation.

Key Considerations Before Final Selection

Sponsors should also evaluate practical implementation factors:

• How quickly the provider can be activated across a global study
• The level of customization required versus standardized workflows
• How exceptions and escalations are handled
• The clarity of communication channels between sponsor, site, and participant support teams

These factors often determine whether a solution scales smoothly or becomes an operational constraint.

As clinical trials become more global and complex, operational infrastructure plays a larger role in determining study success. Travel and expense management is no longer a supporting function—it is part of the execution backbone that keeps trials moving.

For sponsors, the question is not whether to include T&E support, but how to select a partner capable of reducing friction, improving consistency, and protecting participant engagement throughout the study lifecycle.

In that sense, the right partner is not just managing logistics—they are helping stabilize one of the most variable components in clinical research: participant participation itself.

 

Explore More

Leveraging A Global Network to Exceed Patient Expectations

Colpitts Goes Beyond Travel

Transforming Patient Travel & Expenses into a Driver of Trial Success

Visit us on LinkedIn